iRhythm Technologies (NASDAQ:IRTC - Get Free Report) CAO Marc Wade Rosenbaum sold 816 shares of the firm's stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $128.45, for a total value of $104,815.20. Following the completion of the transaction, the chief accounting officer directly owned 16,706 shares in the company, valued at $2,145,885.70. This trade represents a 4.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Marc Wade Rosenbaum also recently made the following trade(s):
- On Wednesday, February 25th, Marc Wade Rosenbaum sold 4,797 shares of iRhythm Technologies stock. The stock was sold at an average price of $135.42, for a total value of $649,609.74.
- On Tuesday, February 24th, Marc Wade Rosenbaum sold 280 shares of iRhythm Technologies stock. The shares were sold at an average price of $140.91, for a total value of $39,454.80.
iRhythm Technologies Stock Performance
iRhythm Technologies stock opened at $125.85 on Wednesday. The firm has a market capitalization of $4.07 billion, a PE ratio of -89.89 and a beta of 1.09. The stock's 50 day moving average price is $159.40 and its 200 day moving average price is $170.14. The company has a debt-to-equity ratio of 4.25, a quick ratio of 4.48 and a current ratio of 4.63. iRhythm Technologies has a one year low of $92.52 and a one year high of $212.00.
iRhythm Technologies (NASDAQ:IRTC - Get Free Report) last released its quarterly earnings results on Thursday, February 19th. The company reported $0.29 earnings per share for the quarter, beating analysts' consensus estimates of $0.02 by $0.27. iRhythm Technologies had a negative net margin of 5.96% and a negative return on equity of 28.15%. The business had revenue of $208.89 million during the quarter, compared to analyst estimates of $202.61 million. During the same period last year, the business earned ($0.04) EPS. The business's revenue was up 27.1% on a year-over-year basis. As a group, sell-side analysts expect that iRhythm Technologies will post -1.98 EPS for the current fiscal year.
Analyst Ratings Changes
A number of equities research analysts have weighed in on the company. Truist Financial restated a "buy" rating and set a $200.00 price objective (down from $215.00) on shares of iRhythm Technologies in a research note on Friday, February 20th. Canaccord Genuity Group decreased their price target on shares of iRhythm Technologies from $212.00 to $198.00 and set a "buy" rating for the company in a research report on Friday, February 20th. JPMorgan Chase & Co. dropped their price target on shares of iRhythm Technologies from $240.00 to $215.00 and set an "overweight" rating for the company in a research note on Friday, February 20th. Wall Street Zen raised shares of iRhythm Technologies from a "hold" rating to a "buy" rating in a report on Saturday, February 21st. Finally, Robert W. Baird decreased their price objective on shares of iRhythm Technologies from $220.00 to $200.00 and set an "outperform" rating for the company in a report on Friday, February 20th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $211.62.
Check Out Our Latest Stock Analysis on iRhythm Technologies
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of IRTC. Root Financial Partners LLC bought a new stake in shares of iRhythm Technologies during the 3rd quarter valued at about $30,000. Measured Wealth Private Client Group LLC acquired a new position in iRhythm Technologies in the third quarter valued at approximately $30,000. GAMMA Investing LLC grew its holdings in shares of iRhythm Technologies by 48.4% during the fourth quarter. GAMMA Investing LLC now owns 184 shares of the company's stock valued at $33,000 after purchasing an additional 60 shares during the last quarter. Smartleaf Asset Management LLC raised its position in shares of iRhythm Technologies by 100.0% during the 3rd quarter. Smartleaf Asset Management LLC now owns 198 shares of the company's stock worth $34,000 after purchasing an additional 99 shares during the period. Finally, FNY Investment Advisers LLC bought a new stake in shares of iRhythm Technologies in the 3rd quarter worth approximately $34,000.
Trending Headlines about iRhythm Technologies
Here are the key news stories impacting iRhythm Technologies this week:
- Positive Sentiment: Management raised FY‑2026 revenue guidance to $870.0M–$880.0M versus consensus of ~$817.3M, signaling stronger top‑line growth and execution on demand — though EPS guidance was not specified, leaving some earnings uncertainty for the year.
- Neutral Sentiment: Analyst coverage is being reworked: several firms trimmed price targets even as they maintain Buy/Overweight stances; commentary notes the story is “shifting” as targets reset while management holds guidance, which can drive mixed reactions as analysts reconcile growth with profitability timelines. Read More.
- Negative Sentiment: Clustered insider selling: multiple senior executives (CAO and several EVPs) sold shares on March 2 — collectively roughly 17,800 shares for ~ $2.3M at an average price ≈ $128.44. Each sale was a mid‑single‑digit percentage reduction in holdings; insiders still retain material stakes, but the concentrated timing of sales is likely weighing on sentiment. Read More.
About iRhythm Technologies
(
Get Free Report)
iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company's flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm's digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.
The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
